MAP2K7 and cancer: Considering our observations of the synergy between MEK and IMPDH inhibitors, as well as the fact that ribavirin RBV stimulates a pathway of T-cell differentiation [56,57] and activates DC cells [58,59] in a way favorable for anti-cancer activity, we tested the effect of this drug combination on the efficacy of an immune therapy.